TLDR:
- J.P. Morgan Private Capital closes inaugural Biotechnology Venture Capital Fund with over $500 million in commitments
- Fund attracts strong support from investors across North America, Europe, the Middle East, and Asia
Full Article:
J.P. Morgan Private Capital, a venture capital and growth equity investment team, recently announced the final close of the first Life Sciences Private Capital offering, 270 Life Sciences Private Capital Fund I, led by Chief Investment Officer Stephen Squinto, Ph.D. and Managing Partner Gaurav Gupta, M.D., M.S.E. The fund surpassed its $500 million target and garnered support from institutional allocators, strategic corporate partners, family offices, high net worth individuals, and JPMorgan Chase & Co.
Dr. Stephen Squinto, Chief Investment Officer and Managing Partner, expressed satisfaction with the quick raise of the inaugural fund within just over a year, nearly twice as fast as similar funds in the past decade. He emphasized the team’s commitment to identifying and supporting highly innovative companies in the biotechnology sector, aiming to shape the future of patient treatments.
The Fund focuses on investing in private biotechnology companies across various stages, modalities, therapeutic areas, and geographies. Portfolio investments include companies in cardiometabolic disease, oncology, immunology, and genetic medicines, with a goal to utilize J.P. Morgan’s scale and resources to add value to the companies.
Gaurav Gupta, M.D., M.S.E., Managing Partner of J.P. Morgan Life Sciences Private Capital, expressed gratitude for the support of investors and strategic advisors, highlighting the firm’s aspiration to become a partner of choice for researchers and entrepreneurs in the biotechnology industry.
J.P. Morgan Private Capital, part of J.P. Morgan Global Alternatives, provides financing solutions for private companies with a focus on venture and growth investing in sectors like consumer, technology, and life sciences. The platform manages various funds, including the newly closed 270 Life Sciences Private Capital Fund I.
